ArticleFrontiers in microbiology2019
Molecular Epidemiology of Multidrug-Resistant
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- High prevalence of antimicrobial resistance genes in multidrug-resistant-ESBLs-producingIranian journal of microbiology · 2024Article
- In Vitro Synergistic Activity of Rifampicin Combined with Minimal Effective Antibiotic Concentration (MEAC) of Polymyxin B Against Extensively Drug-Resistant, Carbapenem-, and Polymyxin B-Resistant Klebsiella pneumoniae Clinical Isolates.Current microbiology · 2024Article
- High-risk clones of carbapenem resistant Klebsiella pneumoniae recovered from pediatric patients in Southern Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- First report of aFrontiers in cellular and infection microbiology · 2024Article
- Clinical and epidemiological characteristics of multi-drug resistantJournal of medicine and life · 2024Article
- A novel antibacterial approach of Cecropin-B peptide loaded on chitosan nanoparticles against MDR Klebsiella pneumoniae isolates.Amino acids · 2023Article
- Genotypic Characterization of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Molecular Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Novel Insights intoMicrobiology spectrum · 2022Article
- Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli.Scientific reports · 2022Article
- The Spread of NDM-1 and NDM-7-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Efficacious antibacterial potency of novel bacteriophages against ESBL-producingIranian journal of microbiology · 2021Article
- Primary lung abscess due to multidrug-resistantBMJ case reports · 2021Article
- Genomic insights into the diversity, virulence and resistance ofMicrobial genomics · 2021Article
- An outbreak of ertapenem-resistant, carbapenemase-negative and porin-deficient ESBL-producingGerms · 2021Article
- Genetic Diversity, Antimicrobial Resistance Pattern, and Biofilm Formation inBioMed research international · 2021Article
- Article
- Profile of Bacteria with ARGs Among Real-World Samples from ICU Admission Patients with Pulmonary Infection Revealed by Metagenomic NGS.Infection and drug resistance · 2021Article
- Epidemiology of β-Lactamase-Producing Pathogens.Clinical microbiology reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.